← FDA DRUG APPROVALS

FDA ANDA · ANDA074520

OXYBUTYNIN CHLORIDE

Sponsor: LANNETT CO INC

APPLICATION
ANDA074520
TYPE
ANDA
ORIGINAL APPROVAL
1996-03-29
LATEST ACTION
2011-11-02
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Prescription

Products

OXYBUTYNIN CHLORIDEPrescription
OXYBUTYNIN CHLORIDE 5MG/5ML · SYRUP · ORAL

Approval history

2011-11-02Labeling · Supplement 5AP
2010-09-20Labeling · Supplement 4AP
2001-07-11Manufacturing (CMC) · Supplement 3AP
1999-03-04Manufacturing (CMC) · Supplement 2AP
1999-03-04Manufacturing (CMC) · Supplement 1AP
1996-03-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →